With a just-completed $100 million common stock financing, Flame Biosciences Inc. plans to target the inflammasome, a protein complex that sets off innate immune responses by activating the cytokines IL-1beta and IL-18.

PERTH, Australia – Starpharma Holdings Ltd. completed a AU$45 million (US$32 million) placement to domestic and international investors that will see it advance its COVID-19 antiviral nasal spray. The treatment is based on the company’s antiviral dendrimer, SPL-7013, which inactivates viruses by blocking the interaction between viral surface proteins and the human cell receptor proteins.

PERTH, Australia – Brandon Capital announced the launch of Ena Respiratory Pty Ltd., which has developed a nasal treatment to boost the natural immune system to fight common colds and flu and has proved successful in reducing COVID-19 viral replication.

PERTH, Australia – Sydney-based Recce Pharmaceuticals Ltd. completed a placement of AU$27.95 million (US$19.69 million) to advance its synthetic anti-infective pipeline.

TORONTO – Toronto-based Oncall Health Inc. has raised CA$7.9 million (US$6 million) in series A funding to help health care organizations lessen COVID-19’s impact on their EMR and other operational programs. An even more ambitious goal, said CEO Nicholas Chepesiuk, is to streamline delivery of virtual health care across a range of small to large U.S.-based organizations “in a way that makes sense for their brand and their workflow.”